Speaker: Li Hui, MD, PhD. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston
Therapeutic development of antibodies and antibody-based drugs is a multi-year process that involves high cost and significant risk. In recent years, a common discovery approach to ensure the quality of new anti-human therapeutic antibodies is to express select human immunoglobulin genes in mice. In this webinar, we highlighted the advantages of therapeutic discovery using RenMabTM mice, which were engineered to contain the entire human immunoglobulin variable region in situ. Similarly, second-generation models (RenLiteⓇ and RenNanoTM mice) offer specialized solutions for the discovery of bispecific/multispecific antibodies or nanobodies. Finally, case study data showcased the advantages of working with Biocytogen’s antibody discovery service team to accelerate discovery for your target or targets of interest.
